drugset / Trial / NCT00925990
CTS-1027 in Interferon-Naive Hepatitis C Patients
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The study is intended to determine whether CTS-1027 either alone or in combination with ribavirin is safe and effective in Hepatitis C patients who have not previously been treated with interferon.
Timeline
- Start
- 2009-06
- Primary completion
- 2010-05
- Completion
- 2010-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CTS-1027 | Small molecule | 15 mg | — |
| Subject | Ribavirin | Small molecule | 1000 mg | — |
| Subject | Ribavirin | Small molecule | 1200 mg | — |